CV Guidance For Diabetes Drugs Will Stick: An Interview With FDA’s Mary Parks
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s head of metabolism and endocrinology products makes sense of new data on glycemic control, addresses Avandia flak.
You may also be interested in...
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”